IgA kappa/IgA lambda heavy/light chain assessment in the management of patients with IgA myeloma
Eileen M. Boyle(BMW (Germany)), Xavier Leleu(Inserm), Susanna Schraen‐Maschke(Université de Lille), Hélène Demarquette(Ikerbasque), Thierry Façon(Université de Lille), Sarah Bonnet(Hôpital Saint Eloi), Guillemette Fouquet(Centre Hospitalier Universitaire de Lille), Salomon Manier(Université de Lille), Charles Herbaux(Centre Hospitalier Universitaire de Lille), Stéphanie Guidez(Inserm), Hervé Avet‐Loiseau(Institut universitaire du cancer de Toulouse Oncopole), Bernadette Hennache(Université de Lille), Rémy Duléry(Dana-Farber Cancer Institute), Marie Pierre Noel(Hôpital Claude Huriez), Brigitte Onraed, Philippe Moreau(Centre National de la Recherche Scientifique), Stephen J. Harding, Claire Mathiot(Institut Curie), Marie Odile Petillon(Hôpital Claude Huriez), Jean‐Luc Faucompré(Université de Lille)
Cited by 36
Related Papers
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis
|American Journal of Hematology|2005|1.4k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
|New England Journal of Medicine|2016|1.1k